Cart
sales@molnova.com
Home - Products - Wnt/Notch/Hedgehog - Wnt/beta/catenin - Vantictumab

Vantictumab

CAS No. 1345009-45-1

Vantictumab( —— )

Catalog No. M36901 CAS No. 1345009-45-1

Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 613 In Stock
10MG 938 In Stock
25MG 1454 In Stock
50MG 1841 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Vantictumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
  • Description
    Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Wnt/Notch/Hedgehog
  • Target
    Wnt/beta/catenin
  • Recptor
    Wnt/beta-catenin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1345009-45-1
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830.?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • TNIK-IN-5

    TNIK-IN-5 is an inhibitor of TNIK and can be used in studies about the treatment of anti-tumor and anti-inflammatory diseases.

  • JW74

    JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling (IC50: 420 nM).

  • Wnt/β-catenin agonis...

    Wnt/β-catenin agonist 4 is an agonist of Wnt that activates Wnt/β-catenin signaling and directs signaling.

Sign In Join Free